Osmind, a Palo Alto, CA-based healthcare technology startup providing software and clinical insights for mental health, raised $2M in seed funding.
The round was led by General Catalyst, with participation from What If Ventures, 20|20 Fund, Jeffrey Leiden MD, PhD (Executive Chairman of Vertex Pharmaceuticals), Alice Zhang (co-founder and CEO of Verge Genomics), and a number of other prominent healthcare executives. Osmind is also backed by Y Combinator and Pear VC.
The company intends to use the funds to accelerate the development and expansion of its electronic health record software and analytics platform leveraged by providers and researchers working with treatment-resistant mental health populations.
Led by Lucia Huang, co-founder and CEO, and Jimmy Qian, co-founder and COO, Osmind is a public benefit corporation that builds software for mental health providers, patients, and researchers and generates insights to advance the development of new therapies, diagnostics, and care management programs.
The software enables patient engagement, remote monitoring, and data-driven clinical decision-making while automating administrative aspects of clinical care and practice management. The platform also aggregates insights to accelerate research and development of new treatments and diagnostics.
Launched in June 2020, the organization currently serves over 20,000 mental health patients in over 125 practices in over 30 states, including some of the largest treatment-resistant mental health clinics in the country.